The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The ‘therapeutic chelation’ approach to treating Alzheimer’s disease (AD) evolved from the metals hypothesis, with the premise that small molecules can be designed to prevent transition metal-induced amyloid deposition and oxidative stress within the AD brain. Over more than twenty years, countless in vitro studies have been devoted to characterizing metal binding, its effect on Aβ aggregation, ROS production and in vitro toxicity. Despite a lack of evidence for any clinical benefit, the conjecture that therapeutic chelation is effective approach for treating AD remains widespread. Here, the author plays the devil’s advocate, questioning the experimental evidence, the dogma and the value of therapeutic chelation, with a major focus on the role of copper ions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“…Aβ and AD is indirect (Herrup, 2015), soluble Aβ oligomers are widely viewed as toxic intermediates responsible for AD pathology (McLean et al., 1999; Selkoe, 2008) and sporadic AD has been associated with an inefficient clearance of Aβ from the central nervous system (Mawuenyega et al., 2010).”
BackgroundHydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · cited 1×
“…exogenous application of Aβ to cultured cells appears capable of causing oxidative damage that can be prevented by metal chelators or antioxidants (Behl et al., 1992, 1994; Manelli and Puttfarcken, 1995; Rosales-Corral et al., 2012), distinguishing direct metal-Aβ redox cycling from downstream…”
BackgroundNeurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 4×
“…2001); Met35 reduces Cu2+(Aβ) to an air-stable Cu+(Aβ) complex (Barnham et al., 2003a; Ciccotosto et al., 2004); Cu2+ cannot displace Zn2+ from Aβ1−40 (Bush et al., 1994b); the affinity of Aβ1−42 for Cu 2+ is 10 attomolar, seven orders of magnitude higher than that of Aβ1−40 (Atwood et al.,…”
BackgroundResultInfluentialCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., & Butterfield, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3270 · Cited by 1,086 · cited 2×
“…dismutase-like di-copper binding site (Curtain et al., 2001; Tickler et al., 2005; Smith et al., 2006); Aβ generates ROS in the absence of metal ions (Hensley et al., 1994; Turnbull et al., 2001); Met35 reduces Cu2+(Aβ) to an air-stable Cu+(Aβ) complex (Barnham et al., 2003a; Ciccotosto et al.,…”
BackgroundThe Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060 · cited 1×
“Other potential physiological functions of Aβ1−40/42 have been proposed, as an antimicrobial peptide (Soscia et al., 2010; Kumar et al., 2016) and as a cerebrovascular sealant (Atwood et al., 2003), although any role for copper ions in these contexts remains to be established.”
Background
Cited by
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Taylor, A. A., Tsuji, J. S., Garry, M. R., McArdle, M. E., Goodfellow, W. L., Adams, W. J., & Menzie, C. A. (2020) · Environmental Management · doi:10.1007/s00267-019-01234-y · Cited by 512
Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications
Gromadzka, G., Tarnacka, B., Flaga, A., & Adamczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239259 · Cited by 339
Copper and Zinc Dysregulation in Alzheimer’s Disease
Sensi, S. L., Granzotto, A., Siotto, M., & Squitti, R. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.10.001 · Cited by 285
Puentes-Díaz, N., Chaparro, D., Morales-Morales, D., Flores-Gaspar, A., & Alí-Torres, J. (2023) · ACS Omega · doi:10.1021/acsomega.2c06939 · Cited by 67
Metadata
- Authors
- Drew, S. C.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-06-02
- Volume
- 11
- Pages
- 317-317
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2621287228
- Cited by
- 91
- References
- 37
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. https://app.cochat.ai/papers/10.3389/fnins.2017.00317
- The paper
- Drew, S. C. (2017). The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2017.00317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.